Approval
Gevalka Wins EU Approval
The European Commission approved Gevalka (ensartinib) for adults with ALK-positive advanced non-small cell lung cancer. Betta states that ensartinib is the first China-developed ALK inhibitor approved in China, the United States and the European Union. A published adjuvant study reported an 80% reduction in recurrence risk; the company cautions that future sales remain uncertain.
- Drugensartinib
- CompanyBetta Pharmaceuticals
- TargetAnaplastic lymphoma kinase receptor tyrosine kinase
- TargetTropomyosin-related receptor kinase A
Written by Gosset from public sources. Source types: Press release · SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.